Across TCGA pan-cancer cohorts, SLC16A14P1 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SLC16A14P1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SLC16A14P1 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC16A14P1 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and KICH are the cancer types where SLC16A14P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC16A14P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.227	<.001	12	view →
KIRP	All	All	−0.195	<.001	11	view →
KICH	All	II,III,IV	−0.334	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SLC16A14P1 RNA expression & survival · all SLC16A14P1 data types